Centiva Capital LP lowered its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 79.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,127 shares of the medical research company's stock after selling 8,382 shares during the quarter. Centiva Capital LP's holdings in IQVIA were worth $418,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in IQV. Synergy Asset Management LLC purchased a new position in IQVIA during the fourth quarter worth $33,000. GKV Capital Management Co. Inc. bought a new position in IQVIA in the 4th quarter valued at $39,000. Lee Danner & Bass Inc. purchased a new position in shares of IQVIA during the fourth quarter worth approximately $44,000. Zions Bancorporation N.A. raised its position in IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after purchasing an additional 85 shares in the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in IQVIA during the fourth quarter worth $60,000. Institutional investors own 89.62% of the company's stock.
IQVIA Stock Down 3.5%
Shares of IQV traded down $5.39 during mid-day trading on Tuesday, reaching $150.74. The company's stock had a trading volume of 2,499,662 shares, compared to its average volume of 1,491,694. The business has a fifty day moving average of $163.31 and a 200 day moving average of $187.68. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 1 year low of $135.97 and a 1 year high of $252.88. The company has a market cap of $26.08 billion, a price-to-earnings ratio of 20.10, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34.
IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.63 by $0.07. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The business had revenue of $3.83 billion for the quarter, compared to analysts' expectations of $3.77 billion. During the same quarter last year, the business earned $2.54 earnings per share. The firm's quarterly revenue was up 2.5% compared to the same quarter last year. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on IQV shares. JPMorgan Chase & Co. lowered their price target on IQVIA from $240.00 to $232.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 18th. BTIG Research cut shares of IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. Citigroup decreased their price target on IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Morgan Stanley increased their target price on IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 11th. Finally, UBS Group reduced their price target on shares of IQVIA from $255.00 to $185.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Eight equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $231.71.
Read Our Latest Stock Analysis on IQV
IQVIA Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Articles
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
